Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glenmark Reaches Eight-Figure Settlement In US Zetia Antitrust Case

Indian Firm Brokers Settlement With One Of Three Plaintiff Classes

Executive Summary

A five-year old case on the cusp of trial involving Glenmark, Merck and the originator’s Zetia has produced a settlement dealing defendants out of the claims – for one class of plaintiffs at least.

You may also be interested in...

US Court Signs Off $70m Glenmark, Merck Settlement In Zetia ‘Pay-For-Delay’ Case

Months after signing off on claims from two other sets of plaintiffs, a US district court in Virginia has approved a settlement agreement with a third class to put to bed antitrust claims that Glenmark and Merck & Co conspired illegally to delay generic competition to Merck’s Zetia blockbuster.

Glenmark Lays Out US Flovent Plans, Discusses Growing Debt Pile

India’s Glenmark is hoping that its proposed generic version of GlaxoSmithKline’s Flovent will benefit from a limited competition market, as it continues to plan a filing with the US Food and Drug Administration.

US Court Provides Opportunity For Lupin And Zydus To Debut Generic Myrbetriq

Lupin and Zydus are targeting a market worth at least $1bn a year – and more than $2.4bn all told – after both in quick succession announcing the launch of generic versions of Astellas Pharma’s Myrbetriq treatment for overactive bladder.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts